Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Paul K. Paik,Enriqueta Felip, R. Veillon,Hiroshi Sakai, A. Cortot,Marina Chiara Garassino,Julien Mazières,Santiago Viteri,Hélène Senellart,Jan Van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conté,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim, Gee Chen Chang, Chia‐Lin Tsai,James Chih‐Hsin Yang, Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,Josef Straub,Andreas Johne, J. Scheele,John V. Heymach,Xiuning Le

The New England Journal of Medicine（2020）

引用 169|浏览3

暂无评分

摘要

A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.

查看译文

关键词

lung cancer,skipping mutations,small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要